基本信息来源于合作网站,原文需代理用户跳转至来源网站获取       
摘要:
In recent years, prostate cancer has been known to have an increasing incidence worldwide. In 2012, prostate cancer was recognized as the second most frequent cancer to occur in men and fifth leading cause of cancer mortality in men. It is known to affect one of every eight men in the world, and even more common in men above the age of 65. However, the long-term survival rate for an average cancer patient continues to decline, creating a need for therapies that could enhance survival rate with favorable advantages. With the minimal side effects and toxicity of the new treatments, it is obvious that these new treatments are the way forward in fighting cancer. This review elaborates the new therapy for prostate cancer treatment that has been developed in very recent times. The goal is not only to create awareness of these new treatments but also gives patients as well as doctors more treatment options. This review builds a foundation on the knowledge of cancer, importantly cancer immunology, and also forms groundwork majorly on prostate cancer, focusing on the mechanism of how immunotherapy could be a better choice over the previously common prostate cancer treatments, proposing a perspective on future directions in the treatment of prostate cancer.
推荐文章
内容分析
关键词云
关键词热度
相关文献总数  
(/次)
(/年)
文献信息
篇名 New advances in immunotherapy for prostate cancer
来源期刊 TMR生命研究 学科 生物学
关键词 PROSTATE cancer IMMUNOTHERAPY CAR T-CELL therapy
年,卷(期) tmrsmyj_2019,(4) 所属期刊栏目
研究方向 页码范围 152-159
页数 8页 分类号 Q
字数 语种
DOI
五维指标
传播情况
(/次)
(/年)
引文网络
引文网络
二级参考文献  (0)
共引文献  (0)
参考文献  (0)
节点文献
引证文献  (0)
同被引文献  (0)
二级引证文献  (0)
2019(0)
  • 参考文献(0)
  • 二级参考文献(0)
  • 引证文献(0)
  • 二级引证文献(0)
研究主题发展历程
节点文献
PROSTATE
cancer
IMMUNOTHERAPY
CAR
T-CELL
therapy
研究起点
研究来源
研究分支
研究去脉
引文网络交叉学科
相关学者/机构
期刊影响力
TMR生命研究
季刊
2624-0548
天津市河东区大直沽中路伯苓大厦B座906
出版文献量(篇)
71
总下载数(次)
0
论文1v1指导